Cannabis and Crohn's: A UK Perspective

Crohn's disease, a chronic inflammatory bowel condition, affects millions worldwide, bringing with it debilitating symptoms that significantly impact daily life. For many, finding effective treatments that offer sustained relief remains a continuous challenge. In recent years, there has been a growing interest in alternative therapies, particularly cannabis and its derivatives, such as cannabidiol (CBD), as potential aids for managing this complex condition. While anecdotal reports have often highlighted perceived benefits, robust scientific studies have been scarce. This article delves into a significant UK-focused study that aimed to rigorously evaluate the efficacy of CBD-rich cannabis oil in inducing remission in Crohn's disease, shedding light on what patients and healthcare providers need to know.

Understanding Crohn's Disease and the Search for Relief

Crohn's disease is characterised by inflammation of the digestive tract, which can lead to severe diarrhoea, abdominal pain, fatigue, weight loss, and malnutrition. The inflammation can affect any part of the gastrointestinal tract from the mouth to the anus, but it most commonly affects the small intestine and the beginning of the large intestine. Managing Crohn's often involves a combination of medications, dietary adjustments, and sometimes surgery. Despite these conventional approaches, many individuals continue to experience persistent symptoms, leading them to explore complementary and alternative therapies.

Among these alternatives, cannabis has emerged as a topic of considerable discussion. Both marijuana and CBD, derived from the *Cannabis sativa* plant, have been touted for their potential therapeutic properties. CBD, in particular, has gained traction due to its non-psychoactive nature, meaning it doesn't produce the 'high' associated with tetrahydrocannabinol (THC). Proponents suggest that cannabis might alleviate symptoms such as pain, nausea, and appetite loss, which are common in Crohn's disease. However, the critical question remains: does it address the underlying inflammation that defines the disease, or merely mask the symptoms?

The Study: Investigating CBD-Rich Cannabis Oil for Crohn's

To address the gap in controlled research, a significant single-centre, double-blind, randomised, placebo-controlled trial was conducted. This rigorous study design is considered the gold standard for evaluating medical interventions, helping to minimise bias and provide reliable data. The primary aim was to assess the effect of CBD-rich cannabis oil for the induction of remission in Crohn's disease patients.

Study Design and Methodology

The trial involved 56 patients, with an average age of 34.5 years, equally split between men and women. These participants were randomly assigned to one of two groups: one receiving oral cannabis oil containing 160/40 mg/ml cannabidiol/tetrahydrocannabinol (CBD/THC), and the other receiving a placebo. The treatment period lasted for 8 weeks. Throughout the study, various disease parameters were meticulously assessed both before and after the treatment period. These included the Crohn's Disease Activity Index (CDAI), a widely used measure of disease severity based on symptoms, and the Simple Endoscopic Score for Crohn's Disease (SES-CD), which evaluates the severity of inflammation and ulceration observed during an endoscopy. Additionally, patients' quality of life (QOL) was assessed. In a subgroup of patients, blood samples were collected to measure CBD and THC plasma levels, confirming the absorption of the active compounds.

Key Findings: Clinical and Quality of Life Improvements

The results of the study offered compelling insights into the potential benefits of CBD-rich cannabis oil:

• Crohn's Disease Activity Index (CDAI): At the start of the study, the cannabis group had a median CDAI of 282, which significantly improved to 166 after 8 weeks. In contrast, the placebo group saw only a modest change, from 264 to 237. The statistical analysis showed a significant difference (p < 0.05) in favour of the cannabis group, indicating a notable improvement in clinical symptoms.
• Quality of Life (QOL): The improvement in QOL was even more striking. At baseline, both groups had a median QOL score of 74. After 8 weeks, the cannabis group's QOL score soared to 91, while the placebo group's score remained largely unchanged at 75. This difference was highly statistically significant (p = 0.004), suggesting that CBD-rich cannabis treatment substantially enhanced patients' overall well-being.
• Absorption: The study also confirmed that the oral CBD-rich cannabis extract was well absorbed by the participants, ensuring that the active compounds were indeed reaching the bloodstream.

Lack of Impact on Inflammation and Endoscopic Scores

Despite the significant improvements in clinical symptoms and quality of life, the study revealed a crucial limitation. Inflammatory markers, such as C-reactive protein (CRP) and calprotectin, which are objective indicators of inflammation in the body and gut respectively, remained unchanged in both groups. Furthermore, the Simple Endoscopic Score for Crohn's Disease (SES-CD) showed no significant changes before and after treatment in either the cannabis or placebo group (p = 0.75). This indicates that while patients felt better and reported an improved quality of life, the underlying inflammation and mucosal healing, as measured by these objective markers, were not directly impacted by the cannabis oil.

Here's a summary of the key findings:

Symptom Relief Versus Disease Modification: A Key Distinction

The study's conclusions highlight a critical distinction in the realm of Crohn's disease treatment: the difference between symptomatic relief and actual disease modification. As Dr. Jami Kinnucan, a gastroenterologist at the University of Michigan, succinctly puts it, "We know the effects of cannabis in the gut and brain can have an impact. So, the question raised is: Is there in an improvement objectively? Does inflammatory burden change?"

This research suggests that while CBD-rich cannabis oil can significantly improve a patient's perception of their symptoms and their overall quality of life, it does not appear to alter the underlying inflammatory processes or induce endoscopic remission. This means that patients might feel much better, experience improvements in appetite, sleep, and general well-being, but the disease itself – the inflammation causing damage to the gut – continues its course. For individuals struggling with the daily burden of Crohn's, feeling better and having a higher quality of life is undeniably valuable. It can reduce pain, improve sleep patterns, stimulate appetite, and alleviate anxiety, all of which are common and debilitating aspects of living with a chronic illness.

However, it is crucial to understand that simply feeling better does not equate to the disease being under control. Uncontrolled inflammation can lead to long-term complications, including strictures, fistulas, and an increased risk of colorectal cancer. Therefore, therapies that only address symptoms without tackling the inflammation should be viewed as complementary, not as a replacement for conventional treatments designed to induce and maintain true remission.

Important Considerations Before Exploring Cannabis for Crohn's

Given these findings, what should individuals with Crohn's disease consider if they are contemplating using cannabis products?

First and foremost, the study's conclusion is unequivocal: "Until further studies are available, cannabis treatment in Crohn's disease should be used only in the context of clinical trials." This is a vital recommendation, underscoring the need for more comprehensive research to fully understand the long-term effects, optimal dosages, and potential interactions with other medications.

In the UK, medical cannabis became legal in November 2018, but access is highly restricted. It can only be prescribed by specialist doctors on the General Medical Council's specialist register for a limited number of conditions where licensed medicines have been exhausted. Crohn's disease is not yet on the primary list for routine prescriptions, and obtaining a prescription for cannabis oil would likely require meeting very specific, stringent criteria, often as part of a clinical trial or in exceptional circumstances.

Other considerations include:

• Legality and Sourcing: The legal landscape surrounding cannabis in the UK is complex. While CBD products are widely available, their quality and purity are not always regulated. THC-containing products are prescription-only. Ensuring any product is legally sourced and of verified quality is paramount.
• Side Effects: Cannabis can have side effects, including dizziness, fatigue, dry mouth, and changes in mood or cognitive function, particularly with THC.
• Drug Interactions: Cannabis can interact with other medications, including immunosuppressants often prescribed for Crohn's disease. This could alter the effectiveness or increase the side effects of either substance.
• Lack of Standardisation: Unlike pharmaceutical drugs, cannabis products often lack standardisation in terms of dosage and composition, making it difficult to predict their effects consistently.
• Consult Your Healthcare Professional: It is absolutely essential to discuss any interest in cannabis with your gastroenterologist or GP. Self-medicating with cannabis could interfere with your prescribed treatment plan and potentially worsen your condition by delaying effective anti-inflammatory therapy.

Alternative and Conventional Treatments for Crohn's Disease

While the exploration of cannabis as a complementary therapy continues, it is vital to remember the cornerstone of Crohn's disease management. Conventional treatments aim to reduce inflammation, relieve symptoms, and prevent complications. These often include:

• Anti-inflammatory Drugs: Such as aminosalicylates (5-ASAs) and corticosteroids.
• Immunosuppressants: Medications like azathioprine, mercaptopurine, or methotrexate, which reduce the immune system's activity.
• Biologics: Advanced therapies that target specific proteins involved in the inflammatory process, such as infliximab, adalimumab, or vedolizumab.
• Dietary Management: Specific dietary changes or nutritional support can help manage symptoms and ensure adequate nutrient intake.
• Surgery: In some cases, surgery may be necessary to remove damaged sections of the intestine or to close fistulas.

For those still experiencing symptoms despite conventional treatments, the conversation with your specialist might involve adjusting medications, exploring new biologics, or considering clinical trials for novel therapies. Complementary therapies, including certain dietary approaches or mind-body techniques, can be discussed as adjuncts to standard care, but should not replace it.

Future Research and Outlook

The study discussed here provides valuable initial data, but it is just one step in a much longer research journey. Future studies will need to be larger, conducted over longer periods, and explore different formulations and dosages of cannabis. Research also needs to delve deeper into the specific mechanisms by which cannabis affects the gut and brain, to better understand how it provides symptomatic relief without reducing inflammation. Investigating the potential role of different cannabinoid profiles (e.g., higher THC, different ratios) and delivery methods could also yield further insights. Until such comprehensive data is available, patients and clinicians must proceed with caution, prioritising evidence-based treatments that address the core pathology of Crohn's disease.

Frequently Asked Questions (FAQs)

Q: Can cannabis cure Crohn's disease?
A: Based on current research, including the study discussed, cannabis does not appear to cure Crohn's disease or resolve the underlying inflammation. It may help manage symptoms and improve quality of life, but it is not a curative treatment.

Q: Does cannabis reduce inflammation in Crohn's?
A: The study found no significant changes in inflammatory markers (CRP, calprotectin) or endoscopic scores, suggesting that CBD-rich cannabis oil did not directly reduce the underlying inflammation in Crohn's disease patients.

Q: What's the difference between CBD and THC for Crohn's?
A: CBD (cannabidiol) is non-psychoactive and is often studied for its potential anti-inflammatory and pain-relieving properties without causing a 'high'. THC (tetrahydrocannabinol) is the primary psychoactive compound in cannabis, responsible for the 'high', and may also have pain-relieving and appetite-stimulating effects. The study used a CBD-rich oil that also contained some THC.

Q: Is it legal to use cannabis for Crohn's in the UK?
A: Medical cannabis is legal in the UK but is highly restricted. It can only be prescribed by specialist doctors for specific conditions where other licensed treatments have been exhausted. Crohn's disease is not typically one of these conditions for routine prescription, and access would likely be limited to clinical trials or exceptional circumstances.

Q: Should I stop my current Crohn's medication if I try cannabis?
A: Absolutely not. You should never stop or alter your prescribed Crohn's medication without explicit guidance from your gastroenterologist. Cannabis should only be considered as a potential complementary therapy and, as the study concludes, ideally within the context of clinical trials and under strict medical supervision.

Conclusion

The recent study on CBD-rich cannabis oil for Crohn's disease offers a nuanced and important perspective. While it clearly demonstrates significant improvements in patients' clinical symptoms and, crucially, their quality of life, it also highlights that these benefits did not correlate with a reduction in objective inflammatory markers or endoscopic healing. This suggests that cannabis may be a valuable tool for symptomatic management and improving the daily experience of living with Crohn's, but it does not appear to tackle the root cause of the disease. For individuals in the UK, navigating the legal and medical landscape of cannabis use for Crohn's requires careful consideration and, most importantly, close consultation with healthcare professionals. Until further, more extensive research provides definitive answers, cannabis should be considered only as a potential adjunctive therapy, ideally within a controlled clinical trial setting, and never as a substitute for conventional, inflammation-targeting treatments for this complex condition.

If you want to read more articles similar to Cannabis and Crohn's: A UK Perspective, you can visit the Automotive category.